Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.

MLA

Kejia Zhu, et al. “Expression of HER2 in High-Grade Urothelial Carcinoma Based on Chinese Expert Consensus and the Clinical Effects of Disitamab Vedotin-Tislelizumab Combination Therapy in the Treatment of Advanced Patients.” Frontiers in Pharmacology, Mar. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fphar.2024.1355081.

APA

Kejia Zhu, Yao Chang, Delong Zhao, Andong Guo, Jishuang Cao, Chenrui Wu, Yong Guan, & Sentai Ding. (2024). Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Frontiers in Pharmacology, 1–11. https://doi.org/10.3389/fphar.2024.1355081

Chicago

Kejia Zhu, Yao Chang, Delong Zhao, Andong Guo, Jishuang Cao, Chenrui Wu, Yong Guan, and Sentai Ding. 2024. “Expression of HER2 in High-Grade Urothelial Carcinoma Based on Chinese Expert Consensus and the Clinical Effects of Disitamab Vedotin-Tislelizumab Combination Therapy in the Treatment of Advanced Patients.” Frontiers in Pharmacology, March, 1–11. doi:10.3389/fphar.2024.1355081.